Indivior Pharmaceuticals, Inc.
INDV
Jodie situation report
Indivior Pharmaceuticals, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 5 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
- INDV's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if INDV's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind INDV
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
RYANRyan Specialty Holdings, Inc.partnerFeb 26, 2026 ▾
“Shareholder Claims A class action lawsuit was filed against Indivior PLC, Mark Crossley (the former CEO of the Company), and Ryan Preblick (the CFO of the Company) on August 2, 2024, alleging violations of certain U.S.”
Depended on by
AQSTAquestive Therapeutics, Inc.customerMay 13, 2026 ▾
“Suboxone was launched by our licensee, Indivior, in 2010.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 1 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
INDV is currently a Follower in the organic co-movement group Buprenorphine Pharmaceuticals. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for INDV; it is not active in the latest market snapshot.